KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Depreciation & Amortization (CF) (2019 - 2025)

GoodRx Holdings (GDRX) has disclosed Depreciation & Amortization (CF) for 7 consecutive years, with $23.1 million as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) rose 21.21% to $23.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $85.2 million through Dec 2025, up 22.55% year-over-year, with the annual reading at $85.2 million for FY2025, 22.55% up from the prior year.
  • Depreciation & Amortization (CF) hit $23.1 million in Q4 2025 for GoodRx Holdings, up from $21.4 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $43.6 million in Q4 2023 to a low of $5.4 million in Q1 2021.
  • Historically, Depreciation & Amortization (CF) has averaged $17.6 million across 5 years, with a median of $16.0 million in 2023.
  • Biggest five-year swings in Depreciation & Amortization (CF): surged 180.74% in 2023 and later crashed 56.21% in 2024.
  • Year by year, Depreciation & Amortization (CF) stood at $10.6 million in 2021, then surged by 45.88% to $15.5 million in 2022, then soared by 180.74% to $43.6 million in 2023, then plummeted by 56.21% to $19.1 million in 2024, then increased by 21.21% to $23.1 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for GDRX at $23.1 million in Q4 2025, $21.4 million in Q3 2025, and $19.7 million in Q2 2025.